This company has been acquired
Prometheus Biosciences Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Prometheus Biosciences's earnings have been declining at an average annual rate of -48.4%, while the Biotechs industry saw earnings growing at 32.7% annually. Revenues have been declining at an average rate of 36.5% per year.
Wichtige Informationen
-48.4%
Wachstumsrate der Gewinne
43.0%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 17.0% |
Wachstumsrate der Einnahmen | -36.5% |
Eigenkapitalrendite | -21.6% |
Netto-Marge | -3,768.8% |
Letzte Ertragsaktualisierung | 31 Mar 2023 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22Aufschlüsselung der Einnahmen und Ausgaben
Wie Prometheus Biosciences Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
31 Mar 23 | 4 | -151 | 45 | 0 |
31 Dec 22 | 7 | -142 | 40 | 0 |
30 Sep 22 | 7 | -133 | 29 | 0 |
30 Jun 22 | 7 | -123 | 29 | 0 |
31 Mar 22 | 6 | -108 | 31 | 0 |
31 Dec 21 | 3 | -90 | 29 | 0 |
30 Sep 21 | 3 | -69 | 25 | 0 |
30 Jun 21 | 2 | -50 | 18 | 0 |
31 Mar 21 | 2 | -38 | 14 | 0 |
31 Dec 20 | 1 | -31 | 11 | 0 |
31 Dec 19 | 1 | -17 | 6 | 0 |
Qualität der Erträge: RXDX is currently unprofitable.
Wachsende Gewinnspanne: RXDX is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: RXDX is unprofitable, and losses have increased over the past 5 years at a rate of 48.4% per year.
Beschleunigtes Wachstum: Unable to compare RXDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: RXDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: RXDX has a negative Return on Equity (-21.58%), as it is currently unprofitable.